Royal Bank of Canada’s Ascentage Pharma AAPG Stock Holding History

Royal Bank of Canada’s Portfolio AAPG Stock Details AAPG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	6	–	–	﹤0.01%	7952
2026 Q1	$0	Hold	6	–	–	﹤0.01%	7857
2025 Q4	$0	Buy	+6	New	+$196	﹤0.01%	7795
2025 Q3	–	Sell	-6	Closed	–	–	7653
2025 Q2	$0	Buy	+6	New	+$158	﹤0.01%	7462

Other funds holding AAPG

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Royal Bank of Canada's AAPG Position: Q2 2026 in Review

Royal Bank of Canada held its Ascentage Pharma (AAPG) position steady in Q2 2026 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7952.

Royal Bank of Canada first reported a position in AAPG in Q2 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold AAPG as of Q2 2026.

Royal Bank of Canada held 6 shares of Ascentage Pharma worth $0 as of Q2 2026.
Royal Bank of Canada left its Ascentage Pharma share count unchanged in Q2 2026.
Ascentage Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7952 holding.
Royal Bank of Canada first reported a position in Ascentage Pharma in Q2 2025 and has held it in 4 quarters since.
8 funds tracked by Wall St. Rank held Ascentage Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.